Comparing the Differential Diagnostic Values of <sup>18</sup>F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients

<div><svg height="15.3888pt" id="M13" style="vertical-align:-3.833899pt" version="1.1" viewbox="-0.0498162 -11.5549 14.8809 15.3888" width="14.8809pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M311 0V25C221 32 216 41 216 113V635C162 613 103 594 39 583V559L88 556C131 552 135 546 135 500V113C135 41 131 32 40 25V0H311Z" id="g190-213"></path></g><g transform="matrix(.0091,0,0,-0.0091,3.03,-5.741)"><path d="M246 635C138 635 67 554 67 471C67 401 116 348 178 315C143 296 103 268 87 252C65 231 42 203 42 157C42 50 128 -12 234 -12C319 -12 432 52 432 169C432 256 370 303 299 344C347 376 373 399 381 408C399 430 408 459 408 487C408 569 341 635 246 635ZM235 603C284 603 334 567 334 483C334 420 306 383 273 358C202 393 142 427 142 503C142 552 173 603 235 603ZM245 21C179 21 122 70 122 163C122 219 155 270 204 300C279 263 352 219 352 144C352 66 308 21 245 21Z" id="g190-152"></path></g><g transform="matrix(.013,0,0,-0.013,7.878,.842)"><path d="M493 503C489 551 484 614 483 650H43V622C120 616 128 611 128 525V126C128 40 120 34 40 28V0H312V28C221 34 213 40 213 126V307H316C407 307 412 296 424 227H453V420H424C412 355 407 346 316 346H213V584C213 613 216 616 246 616H322C398 616 419 607 436 579C449 559 455 539 464 499L493 503Z" id="g121-68"></path></g></svg>-FDG (a) and <svg height="15.3888pt" id="M14" style="vertical-align:-3.833899pt" version="1.1" viewbox="-0.0498162 -11.5549 14.8809 15.3888" width="14.8809pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M311 0V25C221 32 216 41 216 113V635C162 613 103 594 39 583V559L88 556C131 552 135 546 135 500V113C135 41 131 32 40 25V0H311Z" id="g190-213"></path></g><g transform="matrix(.0091,0,0,-0.0091,3.03,-5.741)"><path d="M246 635C138 635 67 554 67 471C67 401 116 348 178 315C143 296 103 268 87 252C65 231 42 203 42 157C42 50 128 -12 234 -12C319 -12 432 52 432 169C432 256 370 303 299 344C347 376 373 399 381 408C399 430 408 459 408 487C408 569 341 635 246 635ZM235 603C284 603 334 567 334 483C334 420 306 383 273 358C202 393 142 427 142 503C142 552 173 603 235 603ZM245 21C179 21 122 70 122 163C122 219 155 270 204 300C279 263 352 219 352 144C352 66 308 21 245 21Z" id="g190-152"></path></g><g transform="matrix(.013,0,0,-0.013,7.878,.842)"><path d="M493 503C489 551 484 614 483 650H43V622C120 616 128 611 128 525V126C128 40 120 34 40 28V0H312V28C221 34 213 40 213 126V307H316C407 307 412 296 424 227H453V420H424C412 355 407 346 316 346H213V584C213 613 216 616 246 616H322C398 616 419 607 436 579C449 559 455 539 464 499L493 503Z" id="g121-68"></path></g></svg>-Alfatide II (b) PET/CT images of a lymph node tuberculosis patient. Lymph nodes tuberculosis lesions showed intense <svg height="15.3888pt" id="M15" style="vertical-align:-3.833899pt" version="1.1" viewbox="-0.0498162 -11.5549 14.8809 15.3888" width="14.8809pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M311 0V25C221 32 216 41 216 113V635C162 613 103 594 39 583V559L88 556C131 552 135 546 135 500V113C135 41 131 32 40 25V0H311Z" id="g190-213"></path></g><g transform="matrix(.0091,0,0,-0.0091,3.03,-5.741)"><path d="M246 635C138 635 67 554 67 471C67 401 116 348 178 315C143 296 103 268 87 252C65 231 42 203 42 157C42 50 128 -12 234 -12C319 -12 432 52 432 169C432 256 370 303 299 344C347 376 373 399 381 408C399 430 408 459 408 487C408 569 341 635 246 635ZM235 603C284 603 334 567 334 483C334 420 306 383 273 358C202 393 142 427 142 503C142 552 173 603 235 603ZM245 21C179 21 122 70 122 163C122 219 155 270 204 300C279 263 352 219 352 144C352 66 308 21 245 21Z" id="g190-152"></path></g><g transform="matrix(.013,0,0,-0.013,7.878,.842)"><path d="M493 503C489 551 484 614 483 650H43V622C120 616 128 611 128 525V126C128 40 120 34 40 28V0H312V28C221 34 213 40 213 126V307H316C407 307 412 296 424 227H453V420H424C412 355 407 346 316 346H213V584C213 613 216 616 246 616H322C398 616 419 607 436 579C449 559 455 539 464 499L493 503Z" id="g121-68"></path></g></svg>-FDG uptake and no <svg height="15.3888pt" id="M16" style="vertical-align:-3.833899pt" version="1.1" viewbox="-0.0498162 -11.5549 14.8809 15.3888" width="14.8809pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M311 0V25C221 32 216 41 216 113V635C162 613 103 594 39 583V559L88 556C131 552 135 546 135 500V113C135 41 131 32 40 25V0H311Z" id="g190-213"></path></g><g transform="matrix(.0091,0,0,-0.0091,3.03,-5.741)"><path d="M246 635C138 635 67 554 67 471C67 401 116 348 178 315C143 296 103 268 87 252C65 231 42 203 42 157C42 50 128 -12 234 -12C319 -12 432 52 432 169C432 256 370 303 299 344C347 376 373 399 381 408C399 430 408 459 408 487C408 569 341 635 246 635ZM235 603C284 603 334 567 334 483C334 420 306 383 273 358C202 393 142 427 142 503C142 552 173 603 235 603ZM245 21C179 21 122 70 122 163C122 219 155 270 204 300C279 263 352 219 352 144C352 66 308 21 245 21Z" id="g190-152"></path></g><g transform="matrix(.013,0,0,-0.013,7.878,.842)"><path d="M493 503C489 551 484 614 483 650H43V622C120 616 128 611 128 525V126C128 40 120 34 40 28V0H312V28C221 34 213 40 213 126V307H316C407 307 412 296 424 227H453V420H424C412 355 407 346 316 346H213V584C213 613 216 616 246 616H322C398 616 419 607 436 579C449 559 455 539 464 499L493 503Z" id="g121-68"></path></g></svg>-Alfatide II uptake. The white arrows indicate tuberculosis lesions in porta hepatis lymph nodes.</div>

Contrast Media & Molecular Imaging

fig2

Figure 2

Figure 2: Comparing the Differential Diagnostic Values of <sup>18</sup>F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients 

Contrast Media & Molecular Imaging

Comparing the Differential Diagnostic Values of 18F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients

Figure 2

Comparing the Differential Diagnostic Values of ¹⁸F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients